Articles producció científica> Medicina i Cirurgia

Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern

  • Dades identificatives

    Identificador: imarina:6040509
    Handle: https://hdl.handle.net/20.500.11797/imarina6040509
    Autors:
    García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Resum:
    In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.

  • Altres:

    Autor segons l'article: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Castillo Eraso, Norma Lorena / Martínez Vea, Alberto
    Resum: In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.
    Àrees temàtiques: Nephrology
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: normalorena.castillo@urv.cat alberto.martinez@urv.cat
    Identificador de l'autor: 0000-0002-0819-8096
    Data d'alta del registre: 2024-03-14
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.hindawi.com/journals/crin/2016/7471082/
    Referència a l'article segons font original: Case Rep Nephrol. 2016 7471082-7471082
    Referència de l'ítem segons les normes APA: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos (2016). Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern. Case Rep Nephrol, 2016(), 7471082-7471082. DOI: 10.1155/2016/7471082
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: 10.1155/2016/7471082
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2016
    Tipus de publicació: Journal Publications